Expression and Clinical Significance of Serum Dipeptidyl Peptidase IV Chronic Obstructive Pulmonary Disease

American Journal of the Medical Sciences

Volumn 351, Issue 3, 2016, Pages 244-252

  Chang, Xiao Yue ^a   Yang, Yong ^a   Jia, Xiao Qing ^a   Wang, Yuan ^a   Peng, Li Na ^a   Ai, Xiao Hong ^a   Jiang, Cui Ying ^a   Guo, Jian Hua ^a   Wu, Ting Ting ^a  

^a BAOTOU CENTRAL HOSPITAL   (China)

Author keywords

Chronic obstructive pulmonary disease; Dipeptidyl peptidase IV; Inflammation; Lymphocytes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; BIOLOGICAL MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; REMISSION; SCREENING; BLOOD; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; CASE-CONTROL STUDIES; DIPEPTIDYL PEPTIDASE 4; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING;

EID: 84963542080     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1016/j.amjms.2015.12.011     Document Type: Article

References (24)

1. Global Strategy for the Diagnosis, Management and prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic obstructive Lung Disease (GOLD). Available from: http://www.goldcopd.org/uploads/users/files/GOLD-Report-2013-Feb20.pdf; 2013.
2. P. Burney, A. Jithoo, B.E. Kato, and et al. Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty - a BOLD analysis Thorax 69 2014 465 473
3. M.D. Eisner, N. Anthonisen, D. Coultas, and et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease Am J Respir Crit Care Med 182 2010 693 718
4. I. De Meester, S. Korom, J. Van Damme, and et al. CD26, let it cut or cut it down Immunol Today 20 1999 367 375
5. C. Durinx, A.M. Lambeir, E. Bosmans, and et al. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides Eur J Biochem 267 17 2000 5608 5613
6. K. Ohnuma, N.H. Dang, and C. Morimoto Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function Trends Immunol 29 2008 295 301
7. M. Delgado, J. Leceta, R.P. Gomariz, and et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression Immunol 163 1999 3629 3635
8. G. Larrinaga, L. Blanco, B. Sanz, and et al. The impact of peptidase activity on clear cell renal cell carcinoma survival Am J Physiol Renal Physiol 303 2012 F1584 F1591
9. O.J. Cordero, F.J. Salgado, and M. Nogueira On the origin of serum CD26 and its altered concentration in cancer patients Cancer Immunol Immunother 58 2009 1723 1747
10. M. Javidroozi, S. Zucker, and W.T. Chen Plasma seprase and DPP4 levels as markers of disease and prognosis in cancer Dis Markers 32 2012 309 320
11. J.J. Holst, and C.F. Deacon Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors Diabetologia 48 2005 612 615
12. J. Schade, M. Stephan, A. Schmiedl, and et al. Regulation of expression and function of dipeptidyl peptidase 4 (DP4), DP8/9, and DP10 in allergic responses of the lung in rats J Histochem Cytochem 56 2008 147 155
13. A. Somborac-Bačura, S. Buljević, L. Rumora, and et al. Decreased soluble dipeptidyl peptidase IV activity as a potential serum biomarker for COPD Clin Biochem 45 2012 1245 1250
14. World Health Organisation Guidelines for Controlling and Monitoring the Tobacco Epidemic 1997 Tobacco or Health Programme, WHO Geneva
15. GOLD Executive Commitee. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Revised 2011). www.goldcopd.com.
16. S.W. Lun, C.K. Wong, F.W. Ko, and et al. Increased expression of plasma and CD4+ T lymphocyte costimulatory molecule CD26 in adult patients with allergic asthma J Clin Immunol 27 2007 430 437
17. B.N. Landis, E. Grouzmann, E. Monod, and et al. Implication of dipeptidylpeptidase IV activity in human bronchial inflammation and in bronchoconstriction evaluated in anesthetized rabbits Respiration 75 2008 89 97
18. L. De Chiara, A.M. Rodríguez-Piñeiro, O.J. Cordero, and et al. Soluble CD26 levels and its association to epidemiologic parameters in a sample population Dis Markers 27 2009 311 316
19. -/- mice Eur J Immunol 42 2012 533 540
20. X. Ji, M. Su, J. Wang, and et al. Design, synthesis and biological evaluation of hetero-aromatic moieties substituted pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors Eur J Med Chem 75C 2014 111 122
21. E. Crickx, I. Marroun, C. Veyrie, and et al. DPP4 inhibitor-induced polyarthritis: a report of three cases Rheumatol Int 34 2014 291 292
22. T. Jojima, and Y. Aso Attention to the use of oral anti-diabetic medication in older adults with type 2 diabetes Nihon Rinsho 71 2013 1987 1992
23. T. Saito, K. Ohnuma, H. Suzuki, and et al. Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors Diabetes Res Clin Pract 102 2013 e8 e12
24. C.D. Lauster, T.P. McKaveney, and S.V. Muench Vildagliptin: a novel oral therapy for type 2 diabetes mellitus Am J Health Syst Pharm 64 2007 1265 1273